NightstaRx Raises $45M to Fund Phase III Study with Retinal Disease Gene Therapy
U.K. firm NightstaRx raised $45 million in a Series C financing round to support continued clinical development of its pipeline of retinal gene therapies, including a pending Phase III study with lead candidate NSR-REP1 for treating [more...]
